Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Phase 3BEAM-302Positive

AI Analysis

Summary

Beam Therapeutics announced first patient enrollment in the global pivotal cohort of BEAM-302 trial for Alpha-1 Antitrypsin Deficiency, alongside reporting Q2 2026 financial results.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in global pivotal cohort

Importance:6/10

Sentiment:

0.60

Phase 3AATDGene therapyClinical trialFirst patient dosed

Related Companies

$BEAM

Read the original article

Published by yahoo_finance on August 4, 2026 11:00 AM

Read Original